$3.37 Million in Sales Expected for Liquidia Co. (NASDAQ:LQDA) This Quarter

Equities research analysts predict that Liquidia Co. (NASDAQ:LQDAGet Rating) will post sales of $3.37 million for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Liquidia’s earnings. The highest sales estimate is $3.80 million and the lowest is $3.10 million. Liquidia reported sales of $3.38 million in the same quarter last year, which indicates a negative year-over-year growth rate of 0.3%. The company is expected to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Liquidia will report full-year sales of $16.61 million for the current year, with estimates ranging from $13.03 million to $22.80 million. For the next financial year, analysts forecast that the business will post sales of $52.90 million, with estimates ranging from $27.80 million to $90.30 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover Liquidia.

Liquidia (NASDAQ:LQDAGet Rating) last issued its quarterly earnings results on Thursday, May 12th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.10). During the same period last year, the business earned ($0.21) earnings per share.

Several brokerages have weighed in on LQDA. Zacks Investment Research downgraded Liquidia from a “hold” rating to a “sell” rating in a report on Wednesday, April 6th. HC Wainwright raised their price target on Liquidia from $6.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, February 3rd.

Shares of NASDAQ LQDA opened at $5.31 on Monday. The company has a market cap of $341.67 million, a PE ratio of -6.64 and a beta of 0.33. The business has a 50-day simple moving average of $6.25 and a two-hundred day simple moving average of $5.55. Liquidia has a fifty-two week low of $2.25 and a fifty-two week high of $7.78.

In other news, Director Caligan Partners Lp bought 1,764,705 shares of the firm’s stock in a transaction that occurred on Monday, April 18th. The stock was purchased at an average price of $5.10 per share, with a total value of $8,999,995.50. Following the completion of the acquisition, the director now directly owns 10,093,123 shares of the company’s stock, valued at approximately $51,474,927.30. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 29.50% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Eversept Partners LP increased its position in shares of Liquidia by 55.8% in the fourth quarter. Eversept Partners LP now owns 1,447,898 shares of the company’s stock valued at $7,051,000 after buying an additional 518,849 shares in the last quarter. Harbert Fund Advisors Inc. increased its position in shares of Liquidia by 840.2% in the third quarter. Harbert Fund Advisors Inc. now owns 420,939 shares of the company’s stock valued at $1,162,000 after buying an additional 376,168 shares in the last quarter. Morgan Stanley increased its position in shares of Liquidia by 337.6% in the second quarter. Morgan Stanley now owns 388,312 shares of the company’s stock valued at $1,111,000 after buying an additional 299,571 shares in the last quarter. Soleus Capital Management L.P. purchased a new stake in shares of Liquidia in the fourth quarter valued at approximately $1,127,000. Finally, D. E. Shaw & Co. Inc. increased its position in shares of Liquidia by 113.9% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 368,849 shares of the company’s stock valued at $1,796,000 after buying an additional 196,430 shares in the last quarter. Institutional investors own 27.68% of the company’s stock.

Liquidia Company Profile (Get Rating)

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension.

Featured Articles

Get a free copy of the Zacks research report on Liquidia (LQDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Liquidia (NASDAQ:LQDA)

Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.